Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), andmore than ...

XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the ...

View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.

Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Read why LGND stock is a Buy.

Key Points Interested in Aflac Incorporated? Here are five stocks we like better. Oxford Club strategist Marc Lichtenfeld ...

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset ...

The fair value price target for XOMA Royalty has been reset from US$65.75 to US$39.00, now aligned with the agreed all cash acquisition price. Analysts are centering their narratives on this US$39 ...

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...

This sell reduced Ligand Pharmaceuticals from 5.8% to 4.8% of Ashford Capital Management’s 13F reportable AUM. Top holdings after the filing: NASDAQ:GSAT: $51.3 million (5.7% of AUM) NASDAQ:LGND: ...